Companies · Biotechnology

Pulmair Medical, Inc.

San Diego · Biotechnology

Diligence memoA one-page analyst read on Pulmair Medical, Inc. — recommendation, valuation, rhythm, risks.
$7.5M
Total raised · real
1
Rounds
0.5×
Latest step-up
Top 50%
Sector rank · raised
Series A
Latest stage · inferred · Tue Jul 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Pulmair Medical, Inc. looks over-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.50× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
  • Issuer reports no revenue, yet is modeled well above niche peers.
Dormant
  • Last raise 7.0 yr ago; this sector typically re-raises about every 14 months.
  • Only one round on record and long silent — often defunct, acquired, or gone quiet.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Pulmair Medical, Inc. is one of 4291 Biotechnology companies tracked from San Diego. By capital raised it ranks mid-pack (ahead of 51% of sector peers), and in the upper tier by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
No revenue
Issuer revenue
Rule 506(b)
Reg D exemption
2018
Year incorporated
2019-07-16
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$125M$250M$375M$500MSeries A · 2019-07-01 Raised $6.0M (real) Modeled valuation $217M (est)$6.0M$217MSeries A2019Series A · 2019-07-16 Raised $7.5M (real) Modeled valuation $271M (est)$7.5M$271MSeries A2019Seed · 2019-07-16 Raised $3.6M (real) Modeled valuation $162M (est)$3.6M$162MSeed2019+$7.5M+$3.6MCumulative $17M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Series A$6.0M · 2019
Series A extension$7.5M · 2019
Bridge · Series A-stage$3.6M · 2019smaller follow-on

Stages are modeled from round size (public records carry no series label). No record for: Pre-Seed — the company may have raised it under a different exemption, merged it into an adjacent record, or skipped it. Sequence completeness: 67%.

Modeled valuation trajectory
$271.1M
Base estimate est.
$8.2M
Conservative case
$1.5B
Upside case
$34.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Series A · modeled $216.9M · 2019-07-012019Series A · modeled $271.1M · 2019-07-16Seed · modeled $162.1M · 2019-07-162019
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
7.0 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
0 mo
Avg between rounds
Capital velocity
7.0 yr
On record since
2019
First round
3
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 1.0× above median
This company$7.5M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.7× of median
This company$3.6M
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 4.2× above median
This company$271.1M
Sector median$64.2M

Raised more than 51% of sector peers (real $). Modeled value above 76% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #59 of 216.

This companyCohort peer
$100.0M$1.0B$1.0M$10.0M$100.0MCapital raised (log)TRACT Therapeutics, Inc. · Series A Raised $15.0M · modeled $542.3M (est)Arrakis Therapeutics, Inc. · Series A Raised $28.2M · modeled $542.3M (est)TechAccel, LLC · Series A Raised $15.0M · modeled $541.9M (est)Trident Labs, Inc. · Series A Raised $14.0M · modeled $506.1M (est)Meissa Vaccines Inc · Series A Raised $15.2M · modeled $503.1M (est)Vibe Bioscience Ltd. · Series A Raised $13.9M · modeled $501.1M (est)Trovagene, Inc. · Series A Raised $45.3M · modeled $488.0M (est)Equinox, Inc. · Series A Raised $34.7M · modeled $485.2M (est)Taiga Biotechnologies, Inc. · Series A Raised $37.9M · modeled $484.6M (est)Aruna Biomedical Inc · Series A Raised $22.4M · modeled $480.5M (est)Vibe Bioscience Corp · Series A Raised $13.7M · modeled $476.8M (est)Adarza BioSystems, Inc. · Series A Raised $31.5M · modeled $461.9M (est)Pulmair Medical, Inc. (this company) Raised $7.5M · modeled $271.1M (est)Pulmair Medical, Inc.
CompanyStageRaised · realValue · estvs peer med.
TRACT Therapeutics, Inc.Series A$15.0M$542.3M3.00×
Arrakis Therapeutics, Inc.Series A$28.2M$542.3M3.00×
TechAccel, LLCSeries A$15.0M$541.9M3.00×
Trident Labs, Inc.Series A$14.0M$506.1M2.80×
Meissa Vaccines IncSeries A$15.2M$503.1M2.78×
Vibe Bioscience Ltd.Series A$13.9M$501.1M2.77×
Trovagene, Inc.Series A$45.3M$488.0M2.70×
Equinox, Inc.Series A$34.7M$485.2M2.68×
Taiga Biotechnologies, Inc.Series A$37.9M$484.6M2.68×
Aruna Biomedical IncSeries A$22.4M$480.5M2.66×
Vibe Bioscience CorpSeries A$13.7M$476.8M2.64×
Adarza BioSystems, Inc.Series A$31.5M$461.9M2.56×
Pulmair Medical, Inc. this companySeries A$7.5M$271.1M1.50×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Series A$6.0M2019-07-01$27.3M$216.9M90%
Series A$7.5M2019-07-16$34.1M$271.1M90%
Seed$3.6M2019-07-16$18.3M$162.1M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Series A$6.0M2019-07-01
    • First recorded raise — entered as Series A.
  2. Series A$7.5M2019-07-16
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 14 investors on this round.
  3. Seed$3.6M2019-07-16
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 2.1× smaller than the prior — bridge or down round.
Intelligence
2019 ~Q3
Modeled next raise · ~0mo cadence
$3.6M
Modeled next size est.range $3.6M$5.8M
0.5×
Last step-up
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Marcelo Lima4 other2019-07
James Lenehan1 other2019-07
Erica Snyder2019-07
Herbert Radisch2019-07
Murilo Rocha2019-07
Registry & provenance

Pulmair Medical, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1781989
SEC CIK
2018
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Cryo Venture Debt, LPBiotechnologySeries A$7.5M$271.7Msame sector · same stage
ApoGen Biotechnologies, Inc.BiotechnologySeries A$7.6M$273.5Msame sector · same stage
FB2 Services, Inc.BiotechnologySeries A$7.6M$276.0Msame sector · same stage
Soltego, Inc.BiotechnologySeries A$7.3M$243.7Msame sector · same stage
ETRX Holdings, Inc.BiotechnologySeries A$7.7M$278.4Msame sector · same stage
Ceapro Inc.BiotechnologySeries A$7.7M$278.8Msame sector · same stage
Northern Mosaic LPBiotechnologySeries A$7.3M$263.6Msame sector · same stage
PharmaInvest LLCBiotechnologySeries A$7.7M$279.0Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
PuraCath Medical, Inc.BiotechnologyPre-Seed$19.1M91%
Pulmotect, Inc.BiotechnologySeries A$49.8M89%
Purigen Biosystems, Inc.BiotechnologySeries B$1.4B89%
Pulsario Enterprise Holdings, IncBiotechnologySeries B$199.7M89%
Pulmotherapeutics IncBiotechnologyPre-Seed$1.5M87%
NuVera Medical, Inc.BiotechnologySeries A$423.0M85%
ReCor Medical, Inc.BiotechnologySeries B$873.2M85%
Psyence Biomedical Ltd.BiotechnologySeed$7.4M85%
Frequently asked
How much funding has Pulmair Medical, Inc. raised?
Pulmair Medical, Inc. has raised approximately $7.5M in disclosed capital across 1 recorded financing round, aggregated from public filings.
What is Pulmair Medical, Inc.'s estimated valuation?
Provath's modeled valuation for Pulmair Medical, Inc. is approximately $271.1M (modeled range $8.2M–$1.5B). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Pulmair Medical, Inc. at?
Pulmair Medical, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Tue Jul 16.
What does Pulmair Medical, Inc. do and where is it based?
Pulmair Medical, Inc. operates in the Biotechnology sector, based in San Diego.
Explore related

See where Pulmair Medical, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Pulmair Medical, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.